早期宫颈癌术前盆腔分期中磁共振成像与超声检查的比较:SENTIX研究的事后分析
SENTIX为前瞻性单臂国际多中心研究,纳入2016年5月至2020年10月47个中心690例早期宫颈癌患者,评估术前MRI与超声分期的准确性;MRI与超声在肿瘤大小测量及宫旁、淋巴结评估方面准确性相似,作者认为超声可考虑用于术前盆腔临床分期,尤其在MRI不可及的资源有限地区。
要点
- 超声与MRI在肿瘤大小测量误差≥10 mm、宫旁浸润和淋巴结宏转移检出失败率上无显著差异。
- 超声评估宫旁浸润的阴性预测值为97.0%,MRI为95.3%,两者无显著差异。
- 作者认为超声可考虑作为早期宫颈癌术前盆腔临床分期的一部分,尤其在MRI不可及的地区。
核心结论
- 超声与MRI在早期宫颈癌肿瘤大小、宫旁浸润和淋巴结评估方面与组织学的一致性相似。
- 作者认为超声可考虑用于早期宫颈癌术前盆腔临床分期,尤其在MRI不可及的资源有限地区。
研究设计与样本
- SENTIX为前瞻性单臂国际多中心研究,共47个中心、18个国家参与。
- 2016年5月至2020年10月前瞻性纳入FIGO(2018)IA1伴淋巴血管间隙浸润阳性至IB2期、常见组织学类型且影像学无可疑淋巴结的宫颈癌患者690例。
- 术前强制采用盆腔MRI或超声进行盆腔临床分期,MRI用于322例(46.7%),超声用于298例(43.2%)。
主要发现
- 超声与最终病理的肿瘤大小差异≥10 mm见于39/298例(13.1%),MRI与病理的差异≥10 mm见于53/322例(16.5%)。
- 超声评估宫旁浸润的阴性预测值为97.0%(95%CI 0.95-0.99%),评估淋巴结受累的阴性预测值为94.0%(95%CI 0.91-0.97%)。
- MRI评估宫旁浸润的阴性预测值为95.3%(95%CI 0.93-0.98%),评估淋巴结受累的阴性预测值为94.1%(95%CI 0.92-0.97%)。
- 超声与MRI在肿瘤大小测量(P=0.452)、宫旁浸润检出失败(P=0.624)和前哨淋巴结宏转移检出失败(P=0.876)方面无显著差异。
关键数值与推荐
- 超声与病理肿瘤大小差异≥10 mm的比例为13.1%(39/298),MRI为16.5%(53/322)。
- 超声宫旁浸润阴性预测值97.0%(95%CI 0.95-0.99%),淋巴结受累阴性预测值94.0%(95%CI 0.91-0.97%)。
- MRI宫旁浸润阴性预测值95.3%(95%CI 0.93-0.98%),淋巴结受累阴性预测值94.1%(95%CI 0.92-0.97%)。
- 肿瘤大小测量比较P=0.452,宫旁浸润检出失败比较P=0.624,前哨淋巴结宏转移检出失败比较P=0.876。
临床怎么用
- 作者认为超声可考虑作为早期宫颈癌术前盆腔临床分期的一部分。
- 作者认为在MRI不可及的资源有限地区尤其可考虑使用超声进行术前盆腔临床分期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: SENTIX was a prospective, single-arm, international multicenter study that evaluated sentinel lymph node biopsy without pelvic lymph node dissection in patients with early-stage cervical cancer. We aimed to evaluate the concordance between preoperative imaging modalities (magnetic resonance imaging (MRI) and ultrasound) and final pathology in the clinical staging of early-stage cervical cancer by post-hoc analysis of the SENTIX study data. METHODS: In total, 47 sites across 18 countries participated in the SENTIX study. Patients with Stage IA1/lymphovascular space invasion-positive to IB2 (International Federation of Gynecology and Obstetrics (FIGO) classification (2018)) cervical cancer, with usual histological types and no suspicious lymph nodes on imaging, were prospectively enrolled between May 2016 and October 2020. Preoperative pelvic clinical staging on either pelvic MRI or ultrasound examination was mandatory. Tumor size discrepancy (< 10 mm vs ≥ 10 mm) between imaging and pathology, as well as the negative predictive value (NPV) of MRI and ultrasound for parametrial involvement and lymph node macrometastasis, were analyzed. RESULTS: Among 690 eligible prospectively enrolled patients, MRI and ultrasound were used as the staging imaging modality in 322 (46.7%) and 298 (43.2%) patients, respectively. A discrepancy of tumor size ≥ 10 mm was reported between ultrasound and final pathology in 39/298 (13.1%) patients and between MRI and pathology in 53/322 (16.5%), with no significant difference in the accuracy of tumor measurement between the two imaging modalities. The NPV of ultrasound in assessing parametrial infiltration and lymph node involvement was 97.0% (95% CI, 0.95-0.99%) and 94.0% (95% CI, 0.91-0.97%), respectively, and that of MRI was 95.3% (95% CI, 0.93-0.98%) and 94.1% (95% CI, 0.92-0.97%), respectively, with no significant differences between the parameters. Ultrasound and MRI were comparable regarding the tumor size measurement (P = 0.452), failure to detect parametrial involvement (P = 0.624) and failure to detect macrometastases in sentinel lymph node (P = 0.876). CONCLUSIONS: Pelvic ultrasound examination and MRI had similar concordance with histology in the assessment of tumor size and of parametrial and lymph node invasion in early-stage cervical cancer. Ultrasound examination should be considered part of preoperative pelvic clinical staging in early-stage cervical cancer, especially in limited-resource regions where MRI is unavailable. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Cibula D, Köhler C, Jarkovský J, et al. Magnetic resonance imaging and ultrasound examination in preoperative pelvic staging of early-stage cervical cancer: post-hoc analysis of SENTIX study. Ultrasound Obstet Gynecol. 2025. PMID: 40130299. doi:10.1002/uog.29205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。